| dc.contributor.author | Vergara-Alert, Júlia | |
| dc.contributor.author | Izquierdo-Useros, Nuria | |
| dc.contributor.other | Producció Animal | ca |
| dc.date.accessioned | 2022-09-26T11:35:22Z | |
| dc.date.available | 2022-11-05T23:45:15Z | |
| dc.date.issued | 2022-05-09 | |
| dc.identifier.citation | Vergara-Alert, Júlia, and Nuria Izquierdo-Useros. 2022. "An Anti-SARS-Cov-2 Metabolite Is Reduced In Diabetes". Nature Metabolism 4 (5): 501-502. doi:10.1038/s42255-022-00569-x. | ca |
| dc.identifier.issn | 2522-5812 | ca |
| dc.identifier.uri | http://hdl.handle.net/20.500.12327/1902 | |
| dc.description.abstract | A glucose-like metabolite, which is reduced in the serum of diabetic patients, inhibits the entry of SARS-CoV-2 into key cellular targets. The work led by Cheng and colleagues provides a molecular explanation for the increased risk of severe COVID-19 in patients with diabetes. | ca |
| dc.format.extent | 4 | ca |
| dc.language.iso | eng | ca |
| dc.publisher | Nature Research | ca |
| dc.relation.ispartof | Nature Metabolism | ca |
| dc.rights | Copyright © 2022, Springer Nature Limited | ca |
| dc.title | An anti-SARS-CoV-2 metabolite is reduced in diabetes | ca |
| dc.type | info:eu-repo/semantics/article | ca |
| dc.description.version | info:eu-repo/semantics/acceptedVersion | ca |
| dc.rights.accessLevel | info:eu-repo/semantics/openAccess | |
| dc.subject.udc | 619 | ca |
| dc.identifier.doi | https://doi.org/10.1038/s42255-022-00569-x | ca |
| dc.contributor.group | Sanitat Animal | ca |
